NANO KOREA 2024

The 22nd International Nanotech Symposium & Exhibition

Dr. Anil K. Patri

Food and Drug Administration, USA

Dr. Anil Patri serves as the Director, Nanocore, at the National Center for Toxicological Research, FDA, and Chairs FDA's Nanotechnology Task Force. He serves on the Nanoscale Science, Engineering, and Technology Subcommittee (NSET) on behalf of FDA for inter-agency coordination and chairs several nanotechnology working groups to identify emerging trends, challenges, consensus development and capacity building. His group conducts regulatory science research on emerging topics of interest to FDA, from material characterization, in vitro and in vivo safety and efficacy studies.

Before joining FDA in 2014, Dr. Patri served for a decade as the Deputy Director, Nanotechnology Characterization Laboratory at the Frederick National Laboratories for Cancer Research to oversee pre-clinical development and clinical translation of cancer therapeutic and imaging agents. He conducted applied research for targeted drug delivery at the Center for Biologic Nanotechnology, University of Michigan, after earning a Ph.D. in Chemistry from University of South Florida.